EGFR and esophageal squamous cell carcinoma: Although driver gene mutations have not been detected in ESCC, the somatic mutation rate in ESCC is relatively high compared to other solid tumors, and it may attenuate the therapeutic effect to EGFR-targeted therapy [49].